Patient advocacy groups should stay out of drug approvals | GUEST COMMENTARY

Pharmaceutical company Amylyx has been applauded for keeping its promise to withdraw Relyvrio, a drug for ALS (amyotrophic lateral sclerosis), after the drug failed a post-approval clinical trial. The real story is that evidence never supported the drug’s approval in the first place. A drug company shouldn’t be in the position to decide to sell a drug that has not been shown to be effective. Only effective drugs should receive full approval.

The Food and Drug Administration (FDA) approved...